While generally well-tolerated, some individuals may experience mild gastrointestinal issues or rare allergic reactions
The liquid pharmaceutical composition according to any one of the previous embodiments, comprising no more than 0.09, alternatively 0.08, alternatively 0.07, alternatively 0.06, alternatively 0.05, alternatively 0.04, alternatively 0.03, alternatively 0.02, alternatively 0.01 %(w/w) phenol
For instance, oil-in-water microemulsions utilizing isopropyl myristate as the oil phase and nonionic surfactants like Labrasol have demonstrated improved drug solubility and stability
Research suggests that 1-2 cycles per year may provide optimal longevity benefits, though Dr
Single-peptide protocols often require higher dosages to achieve clinical efficacy, increasing the risk of adverse events
10.1172/jci95147 J